# GRPR

## Overview
The gastrin-releasing peptide receptor (GRPR) gene encodes a G protein-coupled receptor (GPCR) that is integral to various physiological processes. As a member of the GPCR superfamily, the GRPR protein is characterized by its seven transmembrane domain structure, which facilitates its role in signal transduction across cell membranes. The receptor is primarily activated by the neuropeptide gastrin-releasing peptide (GRP), leading to the activation of several intracellular signaling pathways, including phospholipase C (PLC)/protein kinase C (PKC) and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathways. These pathways are crucial for functions such as synaptic plasticity, memory formation, and smooth muscle contraction. GRPR is expressed in various tissues, including the central nervous system and the gastrointestinal tract, and is implicated in both normal physiological functions and pathological conditions, such as cancer and neurological disorders (Czepielewski2011Gastrinreleasing; Roesler2012Gastrinreleasing; Schwartsmann2006GastrinReleasing).

## Structure
The gastrin-releasing peptide receptor (GRPR) is a member of the G protein-coupled receptor (GPCR) superfamily, characterized by a seven transmembrane domain structure. It is a 384-amino acid protein in humans, with the gene located on chromosome Xp22.2-p22.13 (Roesler2012Gastrinreleasing; Patel2006Gastrinreleasing). GRPR is directly coupled to the Gq type of G protein, and its activation leads to increased cellular calcium levels and stimulation of the phospholipase C (PLC)/protein kinase C (PKC) and extracellular signal-regulated protein kinase (ERK)/mitogen-activated protein kinase (MAPK) pathways (Roesler2012Gastrinreleasing).

The receptor is known to undergo post-translational modifications such as glycosylation, which is significant given its complex structure (Palmioli2020Oncell). GRPR can form dimers, contributing to its quaternary structure, although specific details on its secondary and tertiary structures are not provided in the available context (Fonin2019Multifunctionality). The receptor has a high affinity for its natural ligand bombesin, which is crucial for its role in cancer cell proliferation (Palmioli2020Oncell; Patel2006Gastrinreleasing). The structural information on GRPR is essential for developing synthetic analogues with potential therapeutic applications.

## Function
The gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor that plays a crucial role in various physiological processes in healthy human cells. GRPR is primarily involved in the central nervous system (CNS), where it regulates synaptic plasticity, memory, emotional responses, and social interactions. It is highly expressed in brain regions such as the hippocampus and amygdala, influencing memory formation and emotional behavior (Roesler2012Gastrinreleasing).

GRPR is activated by the neuropeptide gastrin-releasing peptide (GRP), leading to increased cellular calcium levels and activation of signaling pathways such as phospholipase C (PLC)/protein kinase C (PKC) and extracellular signal-regulated protein kinase (ERK)/mitogen-activated protein kinase (MAPK) (Roesler2012Gastrinreleasing). These pathways are crucial for processes like memory consolidation and synaptic transmission regulation (Schwartsmann2006GastrinReleasing).

In the gastrointestinal tract, GRPR mediates smooth muscle contraction and regulates gastric acid secretion, contributing to digestive processes (RamosÁlvarez2015Insights). It also plays a role in the immune system by mediating chemotaxis in neutrophils, which is important for inflammatory responses (Czepielewski2011Gastrinreleasing). GRPR's involvement in these diverse physiological functions highlights its significance in maintaining normal cellular and organismal homeostasis.

## Clinical Significance
Mutations and alterations in the expression of the gastrin-releasing peptide receptor (GRPR) gene have been implicated in various diseases. In the context of cancer, GRPR mutations are significant in the progression of colon adenocarcinoma. Specific mutations in the GRPR gene, particularly in the second exon, can render the receptor incapable of binding ligands, affecting receptor function and cellular signaling pathways (Glover2003Increased). Elevated GRPR expression has been observed in the buccal mucosa of patients with head and neck squamous cell carcinoma (HNSCC), suggesting its potential as a biomarker for early detection of this cancer type (Egloff2012Elevated).

In neurological and psychiatric disorders, altered GRPR expression and function have been associated with conditions such as autism, schizophrenia, and Alzheimer's disease. GRPR is considered a candidate gene for autism, with specific genetic alterations, such as an X;8 translocation, observed in some cases (Roesler2007The). In Alzheimer's disease, dysfunctions in GRPR-mediated calcium signaling have been linked to cognitive dysfunction and neurodegeneration (Schwartsmann2006GastrinReleasing). These findings suggest that GRPR plays a role in the pathogenesis of various central nervous system disorders, offering potential therapeutic targets (Roesler2007The).

## Interactions
The gastrin-releasing peptide receptor (GRPR) is involved in various interactions with other proteins, influencing multiple signaling pathways. GRPR is known to interact with Gαq proteins, which are not typically associated with neutrophil migration, suggesting a unique signaling mechanism. This interaction leads to the activation of phospholipase C-β (PLC-β), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK) pathways, which are crucial for processes such as chemotaxis in neutrophils (Czepielewski2011Gastrinreleasing).

GRPR may also interact with other receptors, such as CXCR2, potentially involving heteromerization, which could lead to receptor internalization. This interaction suggests a possible hierarchy or cooperation between these receptors (Czepielewski2011Gastrinreleasing). In cancer cells, GRPR activation is linked to protein kinase C (PKC) and MAPK/extracellular signal-regulated kinase (ERK) pathways, influencing cellular responses like proliferation (Schwartsmann2006GastrinReleasing).

GRPR antagonists have been shown to down-regulate epidermal growth factor (EGF) receptors and reduce the expression of oncogenes, indicating a role in modulating GRPR-related pathways in cancer therapy (Cornelio2007Gastrinreleasing). These interactions highlight GRPR's involvement in both physiological and pathological processes.


## References


[1. (RamosÁlvarez2015Insights) Irene Ramos-Álvarez, Paola Moreno, Samuel A. Mantey, Taichi Nakamura, Bernardo Nuche-Berenguer, Terry W. Moody, David H. Coy, and Robert T. Jensen. Insights into bombesin receptors and ligands: highlighting recent advances. Peptides, 72:128–144, October 2015. URL: http://dx.doi.org/10.1016/j.peptides.2015.04.026, doi:10.1016/j.peptides.2015.04.026. This article has 83 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.peptides.2015.04.026)

[2. (Fonin2019Multifunctionality) Alexander V. Fonin, April L. Darling, Irina M. Kuznetsova, Konstantin K. Turoverov, and Vladimir N. Uversky. Multi-functionality of proteins involved in gpcr and g protein signaling: making sense of structure–function continuum with intrinsic disorder-based proteoforms. Cellular and Molecular Life Sciences, 76(22):4461–4492, August 2019. URL: http://dx.doi.org/10.1007/s00018-019-03276-1, doi:10.1007/s00018-019-03276-1. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-019-03276-1)

[3. (Glover2003Increased) Sarah C. Glover, Maria S. Tretiakova, Robert E. Carroll, and Richard V. Benya. Increased frequency of gastrin‐releasing peptide receptor gene mutations during colon‐adenocarcinoma progression. Molecular Carcinogenesis, 37(1):5–15, April 2003. URL: http://dx.doi.org/10.1002/mc.10117, doi:10.1002/mc.10117. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/mc.10117)

[4. (Czepielewski2011Gastrinreleasing) Rafael Sanguinetti Czepielewski, Bárbara Nery Porto, Lucas Bortolotto Rizzo, Rafael Roesler, Ana Lúcia Abujamra, Larissa Garcia Pinto, Gilberto Schwartsmann, Fernando de Queiroz Cunha, and Cristina Bonorino. Gastrin-releasing peptide receptor (grpr) mediates chemotaxis in neutrophils. Proceedings of the National Academy of Sciences, 109(2):547–552, December 2011. URL: http://dx.doi.org/10.1073/pnas.1110996109, doi:10.1073/pnas.1110996109. This article has 60 citations.](https://doi.org/10.1073/pnas.1110996109)

[5. (Cornelio2007Gastrinreleasing) D.B. Cornelio, R. Roesler, and G. Schwartsmann. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology, 18(9):1457–1466, September 2007. URL: http://dx.doi.org/10.1093/annonc/mdm058, doi:10.1093/annonc/mdm058. This article has 174 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/annonc/mdm058)

[6. (Palmioli2020Oncell) Alessandro Palmioli, Cecilia Ceresa, Farida Tripodi, Barbara La Ferla, Gabriella Nicolini, and Cristina Airoldi. On-cell saturation transfer difference nmr study of bombesin binding to grp receptor. Bioorganic Chemistry, 99:103861, June 2020. URL: http://dx.doi.org/10.1016/j.bioorg.2020.103861, doi:10.1016/j.bioorg.2020.103861. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bioorg.2020.103861)

[7. (Roesler2012Gastrinreleasing) Rafael Roesler and Gilberto Schwartsmann. Gastrin-releasing peptide receptors in the central nervous system: role in brain function and as a drug target. Frontiers in Endocrinology, 2012. URL: http://dx.doi.org/10.3389/fendo.2012.00159, doi:10.3389/fendo.2012.00159. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2012.00159)

[8. (Patel2006Gastrinreleasing) Oneel Patel, Arthur Shulkes, and Graham S. Baldwin. Gastrin-releasing peptide and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1766(1):23–41, August 2006. URL: http://dx.doi.org/10.1016/j.bbcan.2006.01.003, doi:10.1016/j.bbcan.2006.01.003. This article has 51 citations.](https://doi.org/10.1016/j.bbcan.2006.01.003)

[9. (Egloff2012Elevated) Ann Marie Egloff, Xuwan Liu, Autumn L. Gaither Davis, Brian K. Trevelline, Marike Vuga, Jill M. Siegfried, and Jennifer R. Grandis. Elevated gastrin‐releasing peptide receptor mrna expression in buccal mucosa: association with head and neck squamous cell carcinoma. Head &amp; Neck, 35(2):270–279, March 2012. URL: http://dx.doi.org/10.1002/hed.22963, doi:10.1002/hed.22963. This article has 6 citations.](https://doi.org/10.1002/hed.22963)

[10. (Roesler2007The) Rafael Roesler, Flavio Kapczinski, Joao Quevedo, Felipe Dal Pizzol, and Gilberto Schwartsmann. The gastrin-releasing peptide receptor as a therapeutic target in central nervous system disorders. Recent Patents on CNS Drug Discovery, June 2007. URL: http://dx.doi.org/10.2174/157488907780832742, doi:10.2174/157488907780832742. This article has 5 citations.](https://doi.org/10.2174/157488907780832742)

[11. (Schwartsmann2006GastrinReleasing) G. Schwartsmann, J. Henriques, and R. Roesler. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS &amp; Neurological Disorders - Drug Targets, 5(2):197–204, April 2006. URL: http://dx.doi.org/10.2174/187152706776359673, doi:10.2174/187152706776359673. This article has 73 citations.](https://doi.org/10.2174/187152706776359673)